SCHEMBL7229673

SCHEMBL7229673

COc1ccnc(-c2ccc(C=O)c([N+](=O)[O-])c2)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ERN1 O75460 7/20 0.46
CCR1 P32246 1/20 0.46
CCR5 P51681 1/20 0.46
CCR8 P51685 1/20 0.46
ALDH1A1 P00352 4/20 0.46
MAPT P10636 3/20 0.46
KDM4E B2RXH2 1/20 0.46
CYP3A4 P08684 1/20 0.46
ALOX15 P16050 1/20 0.46
PRKDC P78527 1/20 0.46
HSD17B10 Q99714 1/20 0.46
CBFB Q13951 1/20 0.41
SMN1; SMN2 Q16637 3/20 0.40
NPC1 O15118 2/20 0.40
RAB9A P51151 2/20 0.40
GAA P10253 1/20 0.40
PKM P14618 1/20 0.40
NFKB1 P19838 1/20 0.40
MAPK1 P28482 1/20 0.40
NFKB2 Q00653 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7239282 0.84 CCR1 (0.40) ERN1CCR1CCR5CCR8ALDH1A1
SCHEMBL7239281 0.84 CCR1 (0.40) ERN1CCR1CCR5CCR8ALDH1A1
SCHEMBL7228606 0.83 CCR1 (0.50) CCR1CCR5CCR8ALDH1A1MAPT
SCHEMBL7229501 0.83 CYP2A6 (0.42) ERN1CCR1CCR5CCR8ALDH1A1
SCHEMBL7850225 0.82 MAPT (0.54) CCR1CCR5CCR8ALDH1A1MAPT
SCHEMBL7230041 0.82 MAPT (0.50) CCR1CCR5CCR8ALDH1A1MAPT
SCHEMBL7229835 0.82 CCR1 (0.49) CCR1CCR5CCR8ALDH1A1MAPT
SCHEMBL7230482 0.80 CCR1 (0.46) CCR1CCR5CCR8ALDH1A1MAPT
SCHEMBL7229695 0.80 BACE1 (0.42) ALDH1A1MAPTCYP3A4SMN1; SMN2NPC1
SCHEMBL7229691 0.80 BACE1 (0.42) ALDH1A1MAPTCYP3A4SMN1; SMN2NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6521643-B1 Prevention and/or treatment of nitric oxide synthasey medi-ated diseases such as adult respiratory distress syndrome, myocarditis, synovitis, septic shock, diabetes, ulcerative colitis, cerebral infarction, osteoarthritis FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2003-02-18 US disclosed
EP-1157022-A1 PYRIDINE COMPOUNDS AND THEIR PHARMACEUTICAL USE FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2001-11-28 EP disclosed
WO-2000049015-A1 PYRIDINE COMPOUNDS AND THEIR PHARMACEUTICAL USE FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2000-08-24 WO disclosed